MTOR and intrahepatic cholangiocarcinoma: IL-6 induced programmed death ligand 1 expression through the mTOR pathway in intrahepatic cholangiocarcinoma, suggesting that IL-6 antibodies may help to overcome resistance to immune checkpoint inhibitors in intrahepatic cholangiocarcinoma [175].